"Management is implementing tighter cost controls. The company is capable of annual revenue growth above 10%, which would enable earnings growth of around 20% per year.

"Margins should stay elevated at around 15 to 20; the outside range is attainable given that margins were around 16% last year.

"It seems that the worst for the company's business has passed. Dr. Reddy's could reach the USD $3 billion revenue mark in a couple years, up from current revenue of USD $1.6 billion.

"Dr. Reddy's expects most of the growth to come from global generics, especially from the US. According to management, US growth will be driven by a near doubling of its prescription market share (2.1% in 2008), which would make it a top-five generics company.

"It plans to launch exclusive products in the next three years and to double its portfolio from the current 50 to 100 new drug applications.

"In India the supply chain will be overhauled to improve availability, while new product introductions will be accelerated in order to improve the company's portfolio.

"Russia should remain highly profitable; management is focused on improving market share in Moscow and St. Petersburg, and expanding hospital coverage and the over-the-counter segment.

"Over the long term an aging global population, pressures to contain costs in developed economies, and new markets (e.g., Japan) will drive the company's performance. Buy Dr. Reddy's Laboratories."

Steven Halpern's TheStockAdvisors.com offers a free daily overview of the favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.